Key result
Febuxostat or endothelial Xdh disruption suppresses aortic aneurysm progression in preclinical Marfan syndrome.
Why the study?
Does XOR inhibition with febuxostat or genetic disruption prevent aortic aneurysm progression in Marfan syndrome models?
Does XOR inhibition with febuxostat or genetic disruption prevent aortic aneurysm progression in Marfan syndrome models?
Answers are grounded in this paper and cite their sources.
XOR inhibition with febuxostat suppresses reactive oxygen species generation and mechanosensitive signaling, preventing aortic aneurysm progression in a Marfan syndrome mouse model.
BACKGROUND: Marfan syndrome (MFS) is an inherited disorder caused by mutations in the FBN1 gene encoding fibrillin-1, a matrix component of extracellular microfibrils. The main cause of morbidity and mortality in MFS is thoracic aortic aneurysm and dissection, but the underlying mechanisms remain undetermined. METHODS: To elucidate the role of endothelial XOR (xanthine oxidoreductase)–derived reactive oxygen species in aortic aneurysm progression, we inhibited in vivo function of XOR either by endothelial cell (EC)–specific disruption of the Xdh gene or by systemic administration of an XOR inhibitor febuxostat in MFS mice harboring the Fbn1 missense mutation p.(Cys1041Gly). We assessed the aberrant activation of mechanosensitive signaling in the ascending aorta of Fbn1 C1041G/+ mice. Further analysis of human aortic ECs investigated the mechanisms by which mechanical stress upregulates XOR expression. RESULTS: We found a significant increase in reactive oxygen species generation in the ascending aorta of patients with MFS and Fbn1 C1041G/+ mice, which was associated with a significant increase in protein expression and enzymatic activity of XOR protein in aortic ECs. Genetic disruption of Xdh in ECs or treatment with febuxostat significantly suppressed aortic aneurysm progression and improved perivascular infiltration of macrophages. Mechanistically, mechanosensitive signaling involving FAK (focal adhesion kinase)–p38 MAPK (p38 mitogen-activated protein kinase) and Egr-1 (early growth response-1) was aberrantly activated in the ascending aorta of Fbn1 C1041G/+ mice, and mechanical stress on human aortic ECs upregulated XOR expression through Egr-1 upregulation. Consistently, EC-specific knockout of XOR or systemic administration of febuxostat in Fbn1 C1041G/+ mice suppressed reactive oxygen species generation, FAK–p38 MAPK activation, and Egr-1 upregulation. CONCLUSIONS: Aberrant activation of mechanosensitive signaling in vascular ECs triggered endothelial XOR activation and reactive oxygen species generation, which contributes to the progression of aortic aneurysms in MFS. These findings highlight a drug repositioning approach using a uric acid–lowering drug febuxostat as a potential therapy for MFS.
No takes yet. Share an insight, caveat, or question.
Yagi et al. (2025) studied Marfan syndrome and aortic aneurysm. Endothelial cell-specific disruption of Xdh gene or febuxostat vs. Control MFS mice was evaluated on Aortic aneurysm progression and reactive oxygen species generation. Genetic disruption of Xdh in endothelial cells or treatment with febuxostat significantly suppressed aortic aneurysm progression and ROS generation in a Marfan syndrome mouse model.
Synapse has enriched 10 related papers. Consider them for comparative context: